Phase 3 trials in the United Kingdom: Trial Insights

Filters: Phase: Phase 3 Country / region: United Kingdom Clear all

5,523 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2000	38
2001	74
2002	69
2003	105
2004	128
2005	155
2006	195
2007	179
2008	207
2009	188
2010	202
2011	210
2012	222
2013	243
2014	223
2015	259
2016	210
2017	261
2018	275
2019	253
2020	226
2021	282
2022	236
2023	249
2024	252
2025	254
2026	159

Trials by status
Category	Trials
Completed	3,379
Active, not recruiting	668
Terminated	639
Recruiting	566
Unknown status	198
Enrolling by invitation	29
Withdrawn	22
Not yet recruiting	20
Suspended	2

Top lead sponsors
Category	Trials
Novartis Pharmaceuticals	260
AstraZeneca	256
Hoffmann-La Roche	256
Pfizer	171
GlaxoSmithKline	164
Eli Lilly and Company	160
Sanofi	139
Novo Nordisk A/S	124
Merck Sharp & Dohme LLC	123
Bristol-Myers Squibb	119

Top conditions
Category	Trials
Breast Neoplasms	209
Diabetes Mellitus, Type 2	182
Carcinoma, Non-Small-Cell Lung	179
Neoplasms	124
Prostatic Neoplasms	111
Neoplasm Metastasis	109
Diabetes Mellitus	96
Multiple Myeloma	94
Pulmonary Disease, Chronic Obstructive	93
Arthritis, Rheumatoid	77

Trials

Showing 1 to 25 of 5,523. Each trial links to its page on Pharma Observatory.

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy NCT07789483Phase 3Not yet recruitingAlexion Pharmaceuticals, Inc.Started 2027
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis NCT07335562Phase 3Not yet recruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyStarted 2027
Stratification and Treatment in Early Psychosis Study -ASSIST NCT07326124Phase 3Not yet recruitingUniversity of OxfordStarted 2027
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis NCT07441408Phase 3Not yet recruitingBristol-Myers SquibbStarted 2026
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" NCT07281027Phase 3Not yet recruitingYale UniversityStarted 2026
Stratification and Treatment in Early Psychosis Study - PROMOTE NCT07434973Phase 3Not yet recruitingUniversity of OxfordStarted 2026
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma NCT07815574Phase 3Not yet recruitingScancell LtdStarted 2026
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease NCT07717411Phase 3RecruitingHoffmann-La RocheStarted 2026
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma NCT07728188Phase 3Not yet recruitingAbbVieStarted 2026
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity NCT07861100Phase 3Not yet recruitingNovo Nordisk A/SStarted 2026
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease NCT07850063Phase 3Not yet recruitingBoehringer IngelheimStarted 2026
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A NCT07830732Phase 3Not yet recruitingNovo Nordisk A/SStarted 2026
Stratification and Treatment in Early Psychosis Study - ENHANCE NCT06778564Phase 3RecruitingUniversity of OxfordStarted 2026
Study of Serine Supplementation to Protect Vision in MacTel NCT07342439Phase 3Not yet recruitingThe Lowy Medical Research Institute LimitedStarted 2026
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes NCT07668336Phase 3Not yet recruitingEli Lilly and CompanyStarted 2026
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma NCT07768189Phase 3RecruitingCorbus Pharmaceuticals Inc.Started 2026
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression NCT07540988Phase 3RecruitingBoehringer IngelheimStarted 2026
A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) NCT07793409Phase 3RecruitingSanofiStarted 2026
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 3RecruitingCSL BehringStarted 2026
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) NCT07711002Phase 3RecruitingAstraZenecaStarted 2026
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib NCT07623161Phase 3RecruitingTakedaStarted 2026
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned NCT07665450Phase 3RecruitingJanssen Research & Development, LLCStarted 2026
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia NCT07623200Phase 3RecruitingIncyte CorporationStarted 2026
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping NCT07587242Phase 3RecruitingAvidity Biosciences, Inc.Started 2026
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) NCT07624305Phase 3RecruitingAstraZenecaStarted 2026

5,423 more trials match. See them on Pharma Observatory

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease NCT06332534Completion date change2034-12-31 to 2031-01-31October 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Completion date change2030-07-31 to 2029-11-30October 18, 2026
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment NCT06750289Completion date change2028-11-03 to 2026-09-21October 18, 2026
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib NCT03673501Completion date change2026-12-31 to 2027-12-31October 18, 2026
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine NCT04965675Completion date change2026-10-31 to 2027-03-26October 18, 2026
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease NCT06332534Enrollment change110 to 111October 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Enrollment change675 to 699October 18, 2026
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment NCT06750289Enrollment change400 to 130October 18, 2026
Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. NCT07007793Enrollment change250 to 212October 18, 2026
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease NCT06332534Status changeRecruiting to Active, not recruitingOctober 18, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory